
    
      Longitudinal study of circulating and intra-hepatic HBV-specific T-cell immunity in the
      setting of a randomised, controlled, international, multi-centre outpatient trial. The trial
      will randomise HIV/HBV co-infected individuals to different HBV-active antiretroviral therapy
      treatment regimens.

      Study population: Patients with HIV/HBV co-infection who are naive to HIV/HBV therapy, have
      detectable HBV viremia and are willing to start antiretroviral therapy.
    
  